$0.07
TRACON Pharmaceuticals is a biotechnology business based in the US. TRACON Pharmaceuticals shares (TCON) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.06 – a decrease of 29.98% over the previous week. TRACON Pharmaceuticals employs 17 staff and has a trailing 12-month revenue of around $3.2 million.
What's in this guide?
- TCON shares summary
- Compare share dealing platforms
- Is TCON stock a buy or sell?
- Stock performance over time
- Can I short TCON shares?
- Are TCON shares over-valued?
- TRACON Pharmaceuticals's financials
- How volatile are TCON shares?
- Does TRACON Pharmaceuticals pay a dividend?
- Have TCON shares ever split?
- Other common questions
Our top picks for where to buy TRACON Pharmaceuticals stock
- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy TRACON Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TCON. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy TRACON Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
TRACON Pharmaceuticals stock price (NASDAQ: TCON)
Use our graph to track the performance of TCON stocks over time.TRACON Pharmaceuticals shares at a glance
Latest market close | $0.06 |
---|---|
52-week range | $0.03 - $14.75 |
50-day moving average | $0.11 |
200-day moving average | $2.20 |
Wall St. target price | $6.00 |
PE ratio | 0.0088 |
Dividend yield | N/A |
Earnings per share (TTM) | $5.93 |
Is it a good time to buy TRACON Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
TRACON Pharmaceuticals price performance over time
Historical closes compared with the close of $0.052 from 2024-10-15
1 week (2024-10-10) | -36.12% |
---|---|
1 month (2024-09-17) | -59.75% |
3 months (2024-07-17) | -91.75% |
6 months (2024-04-17) | -97.73% |
1 year (2023-10-17) | -69.05% |
---|---|
2 years (2022-10-17) | -96.90% |
3 years (2021-10-15) | 3.78 |
5 years (2019-10-17) | 3.239 |
Is TRACON Pharmaceuticals stock undervalued or overvalued?
Valuing TRACON Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TRACON Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TRACON Pharmaceuticals's P/E ratio
TRACON Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, TRACON Pharmaceuticals shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
TRACON Pharmaceuticals financials
Revenue TTM | $3.2 million |
---|---|
Gross profit TTM | $-13,888,000 |
Return on assets TTM | -59.37% |
Return on equity TTM | -1277.01% |
Profit margin | 162.34% |
Book value | $-0.91 |
Market Capitalization | $177,193 |
TTM: trailing 12 months
TRACON Pharmaceuticals share dividends
We're not expecting TRACON Pharmaceuticals to pay a dividend over the next 12 months.
Have TRACON Pharmaceuticals's shares ever split?
TRACON Pharmaceuticals's shares were split on a 1:20 basis on 9 April 2024. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TRACON Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for TRACON Pharmaceuticals shares which in turn could have impacted TRACON Pharmaceuticals's share price.
TRACON Pharmaceuticals share price volatility
Over the last 12 months, TRACON Pharmaceuticals's shares have ranged in value from as little as $0.034 up to $14.746. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TRACON Pharmaceuticals's is 1.356. This would suggest that TRACON Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TRACON Pharmaceuticals overview
TRACON Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co. , Ltd.
Frequently asked questions
What percentage of TRACON Pharmaceuticals is owned by insiders or institutions?Currently 1.732% of TRACON Pharmaceuticals shares are held by insiders and 4.04% by institutions. How many people work for TRACON Pharmaceuticals?
Latest data suggests 17 work at TRACON Pharmaceuticals. When does the fiscal year end for TRACON Pharmaceuticals?
TRACON Pharmaceuticals's fiscal year ends in December. Where is TRACON Pharmaceuticals based?
TRACON Pharmaceuticals's address is: 4350 La Jolla Village Drive, San Diego, CA, United States, 92122 What is TRACON Pharmaceuticals's ISIN number?
TRACON Pharmaceuticals's international securities identification number is: US89237H2094 What is TRACON Pharmaceuticals's CUSIP number?
TRACON Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 89237H209
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question